Mesoporous silica sieves are among the most studied nano-objects due to their stable pore structure and easy preparation. In particular, MCM-41 have attracted increasing research attention due to their chemical versatility. This review focuses on the synthesis and regioselective functionalization of MCM-41 to prepare catalytic systems. The topics covered are: mono and di-functionalized MCM-41 as basic and acid catalysts, catalysts based on metallic complexes and heteropolyacids supported onto MCM-41, metallic nanoparticles embed onto functionalized MCM-41 and magnetic MCM-41 for catalytic purposes.
Combination therapies rely on the administration of more than one drug, with independent mechanisms of action, aiming to enhance the efficiency of the treatment. For an optimal performance, the implementation of such therapies requires the delivery of the correct combination of drugs to a specific cellular target. In this context, the use of nanoparticles (NP) as platforms for the co-delivery of multiple drugs is considered a highly promising strategy. In particular, mesoporous silica nanoparticles (MSN) have emerged as versatile building blocks to devise complex drug delivery systems (DDS). This review describes the design, synthesis, and application of MSNs to the delivery of multiple drugs including nucleic acids for combination therapies.
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers worldwide, characterized by late diagnosis, aggressive progression, and poor response to conventional monotherapies. Combination therapies have emerged as a promising approach to overcome multidrug resistance (MDR), enhance efficacy, and target the complex tumor microenvironment (TME). Nanoparticle-based drug delivery systems (DDSs) have gained significant attention for their ability to co-deliver multiple agents with controlled release profiles. This review comprehensively examines nanoparticle-based platforms developed for PDAC combination therapies, focusing on small-molecule drugs. The systems discussed are drawn from studies published between 2005 and 2025.
29 November 2025 in Journal of Drug Delivery Science and Technology